Who is sponsoring NCT03379493?

NCT03379493 is sponsored by Eureka Therapeutics Inc..

What drugs are being tested in NCT03379493?

Interventions in NCT03379493: ET190L1 ARTEMIS™ T cells.

What condition does NCT03379493 study?

NCT03379493 studies Lymphomas Non-Hodgkin's B-Cell.

Is NCT03379493 still recruiting?

NCT03379493 is currently terminated. Last updated 4 February 2019.

Last reviewed 2019-02-04 · How we verify

NCT03379493

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

Terminated Phase 1 Last updated 4 February 2019

What this trial tests

Phase 1 trial testing ET190L1 ARTEMIS™ T cells in Lymphomas Non-Hodgkin's B-Cell in 4 participants. Terminated before completion.

Timeline

4 April 2018

Primary endpoint
23 December 2018

30 January 2019

Quick facts

Lead sponsor	Eureka Therapeutics Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	4 April 2018
Primary completion	23 December 2018
Estimated completion	30 January 2019
Sites	1 location across United States

Drugs / interventions tested

ET190L1 ARTEMIS™ T cells — full drug profile →

Conditions studied

Lymphomas Non-Hodgkin's B-Cell — all drugs for Lymphomas Non-Hodgkin's B-Cell →

Sponsor

Eureka Therapeutics Inc. — full company profile →

Who can join

18 and older, any sex, with Lymphomas Non-Hodgkin's B-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-randomized, single arm, open-label, single institution, phase I study to determine the maximum tolerated dose (MTD) of ET190L1 ARTEMIS™ T cells in patients ≥ 18 years of age with relapsed or refractory CD19+ Non-Hodgkin's lymphoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release.
Xu Y, Yang Z, Horan LH, Zhang P, et al · · 2018 · cited 102× · PMID 30479831 · DOI 10.1038/s41421-018-0066-6
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.
Li C, Zhou F, Wang J, Chang Q, et al · · 2023 · cited 21× · PMID 36681817 · DOI 10.1186/s13045-023-01402-y
γδ T cells in immunotherapies for B-cell malignancies.
Rimailho L, Faria C, Domagala M, Laurent C, et al · · 2023 · cited 9× · PMID 37426670 · DOI 10.3389/fimmu.2023.1200003

Verify or expand the search:

Other trials of ET190L1 ARTEMIS™ T cells

Trials testing the same drug.

NCT03415399 — Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma · Phase 1 · completed

Other recruiting trials for Lymphomas Non-Hodgkin's B-Cell

Currently open trials in the same condition.

NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT03375619 — Long-term Follow-up Study of Patients Receiving CAR-T Cells · recruiting

Other Eureka Therapeutics Inc. trials

Trials by the same sponsor.

NCT04634357 — ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT04864054 — T-Cell Therapy (ECT204) in Adults With Advanced HCC · Phase 1, PHASE2 · recruiting
NCT04502082 — Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) · Phase 1 · terminated
NCT03998033 — Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma · Phase 1 · terminated
NCT03415399 — Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03379493 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eureka Therapeutics Inc.
Last refreshed: 4 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03379493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing